Spirulina and ulcerative colitis.

UC immunopathology

• Th2/Th9 mucosal inflammation:UC involves IL-13, IL-4, IL-9, and IL-5 skewing (distinct from Crohn’s Th1/Th17). IL-13 directly impairs epithelial barrier tight junction proteins (claudin-2 upregulation increases paracellular permeability), and activates macrophages and mast cells in the lamina propria.
• NOX2 in colonic tissue:Lamina propria macrophages and infiltrating neutrophils in UC lesions show markedly elevated NOX2 expression. Superoxide from NOX2 drives the local oxidative injury to colonocytes and impairs the mucus layer that protects the epithelium from luminal bacteria.
• Butyrate deficiency:Colonocytes derive ~70% of their energy from butyrate, produced by gut microbiota fermentation of dietary fibre. UC is consistently associated with reduced butyrate-producing bacteria (particularly Faecalibacterium prausnitzii and Roseburia species). Butyrate also inhibits NF-κB in colonic epithelium — its deficiency perpetuates inflammation.
• Mucosal barrier dysfunction:Tight junction protein loss increases colonic permeability, allowing luminal microbial products (LPS, peptidoglycans) to activate lamina propria immune cells — creating the self-perpetuating inflammatory cycle.

Spirulina mechanisms relevant to UC

Phycocyanobilin and colonic NOX2

Phycocyanobilin inhibits the same NOX2 enzyme upregulated in UC colonic macrophages and neutrophils. In animal models of colitis (DSS-induced):

• Phycocyanin administration reduced colonic myeloperoxidase activity (a marker of neutrophil infiltration), histological inflammation score, and TNF-α/IL-6 production
• NF-κB activity in colonic tissue was reduced; COX-2 and iNOS expression were suppressed
• These are animal studies (DSS colitis is a standard murine model); human trial data in UC is absent

Polysaccharides and butyrate production

Spirulina polysaccharides are selectively fermented by Bifidobacterium species and butyrate producers:

• Increased Faecalibacterium prausnitzii abundance from spirulina polysaccharide fermentation directly addresses one of UC’s most consistent microbial deficits
• Butyrate produced from spirulina polysaccharides inhibits NF-κB in colonocytes and fuels the colonocyte energy supply that is disrupted in active UC
• This is a complementary mechanism to mesalazine (which also inhibits NF-κB and 5-LOX in colonic tissue)

Iron deficiency in UC

Rectal bleeding is a cardinal UC symptom — iron deficiency from blood loss is very common:

• Ferritin is often falsely normal or elevated in UC due to acute-phase upregulation — ferritin >30 µg/L does not rule out iron deficiency in active inflammation. Check transferrin saturation (<20% indicates functional iron deficiency) and CRP together.
• As with Crohn’s, IV iron is preferred over oral in active UC — luminal iron may worsen mucosal oxidative stress.
• In remission, spirulina’s food-matrix iron alongside vitamin C provides a tolerable maintenance iron source.

Biologic therapy interactions

• Anti-TNF (infliximab, adalimumab, golimumab):Spirulina’s NK cell stimulation and IFN-γ induction could theoretically counter-regulate the immunosuppressive environment. In UC (predominantly Th2), IFN-γ induction by spirulina shifts immune balance away from the Th2 pattern — this might actually be directionally appropriate. The net effect is uncertain; gastroenterologist discussion is required.
• Anti-integrin (vedolizumab):Gut-selective; lower concern than systemic immunosuppressants. Most compatible biologic for concurrent spirulina use.
• Janus kinase (JAK) inhibitors (tofacitinib):JAK inhibitors are broadly immunosuppressive. NK stimulation from spirulina requires specialist discussion.
• Mesalazine (5-ASA):Mechanistically complementary; no interaction concern. 5-ASA inhibits 5-LOX and NF-κB; spirulina NF-κB inhibition and GLA eicosanoid effects are additive in direction.

Remission vs active flare

• Remission:5–10 g/day appropriate. Focus on polysaccharide-driven microbiome support (take with food), phycocyanin anti-inflammatory maintenance, and iron provision for ongoing mild blood loss correction.
• Active flare:Reduce to 1–2 g or pause. Inflamed colon has altered motility, transit, and absorption. NK stimulation during active inflammation adds unpredictability. Prioritise medical management (steroids, 5-ASA, biologics) above supplementation adjustments.
• Reintroduce spirulina gradually as remission is re-established and confirmed by calprotectin normalisation.